# Using Tumor Models to Determine Treatments

> **NCT06813079** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 25 (estimated)

## Conditions studied

- Pancreatic Ductal Carcinoma
- Advanced Cancer
- Epithelial Tumor

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Ponatinib
- **DRUG:** Brigatinib
- **DRUG:** Colchicine
- **DRUG:** Selinexor
- **DRUG:** Abemaciclib
- **DRUG:** Neratinib
- **DRUG:** Doxorubicin
- **DRUG:** Etoposide
- **DRUG:** Ceritinib

## Key facts

- **NCT ID:** NCT06813079
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-17
- **Primary completion:** 2028-02-17
- **Final completion:** 2028-02-17
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06813079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06813079, "Using Tumor Models to Determine Treatments". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06813079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*